Kornimate/medical-research-clean huggingface dataset:
effectiveness of oral albendazole in the treatment of severe acute malnutrition

Conditions: Kwashiorkor; Marasmus

Summary: the benefit of anti-worm therapy as part of the case management of severe acute malnutrition (sam) in the outpatient setting has not previously been studied. this study will compare recovery rates of children with sam treated in the community with locally-produced ready-to-use therapeutic food (rutf) with and without prescribed albendazole as part of their case management.


Eligibility criteria:
inclusion criteria: * 12-59 months old * kwashiorkor and/or marasmus * qualified for home-based therapeutic feeding with rutf exclusion criteria: * obvious congenital or other malformation that makes child a poor candidate for feeding with rutf * unable to consume test-dose of rutf in clinic * parent refusal to participate and return for follow-up
top down versus step up strategies in crohn's disease

Conditions: Crohn's Disease

Summary: the study prospectively compares two treatment algorithms for newly diagnosed crohn's disease: one 'aggressive' treatment with early introduction of immunomodulators and biologicals and one 'standard treatment' with corticosteroids and only later introduction of immunosuppressives and biologicals if disease activity requires that.

this two year open-label randomized trial compares the early use of combined immunosuppression to conventional management in patients with active crohn's disease who have not previously received glucocorticoids, antimetabolites, or infliximab. patients assigned to combined immunosuppression receive azathioprine and 3 infusions of 5 milligrams per kilogram of body weight of infliximab at weeks 0, 2, and 6. retreatment with infliximab and, if ultimately necessary, corticosteroids are used to control disease activity. patients assigned to conventional management receive corticosteroids followed, in sequence, by azathioprine and infliximab. the primary outcome measure is remission without corticosteroids and without bowel resection at weeks 26 and 52.

Eligibility criteria:
inclusion criteria: * age 16 - 75 years * diagnosis of crohn's disease within the past 4 years * no previous treatment with corticosteroids, antimetabolites, or biologic agents. * active crohn's disease, defined by a crohn's disease activity index (cdai)20 score of greater than 200 points for a minimum of 2 weeks prior to randomization. exclusion criteria: * immediate need for surgery * symptomatic stenosis or ileal/colonic strictures with prestenotic dilatation; * signs, symptoms or laboratory tests indicating severe, medical disease; * documented chronic infection * a positive stool culture for pathogens * a positive tuberculin test or a chest radiograph consistent with tuberculosis. * malignancy * allergy to murine proteins * pregnancy * substance abuse

Keywords: crohn's disease immunomodulators biologicals
adult polysomnography primary insomnia cross over study (0928-049)(terminated)

Conditions: Primary Insomnia

Summary: the purpose of this study is determine whether this drug will improve your insomnia in terms of decreasing your time to fall asleep and allowing you to stay asleep longer. the drug will be compared against placebo in order to determine if there's a difference.


Eligibility criteria:
inclusion criteria: * diagnosis of primary insomnia * patient is willing to stay overnight at a sleep laboratory for a total of 7 nights * patient is willing to avoid alcohol on psg visits * patient will avoid napping during the course of the study * patient's bedtime is between 9pm and 1am exclusion criteria: * history of substance abuse, bipolar disorder or psychotic disorder * difficulty sleeping due to other medical condition * history of narcolepsy, circadian rhythm sleep disorder, parasomnia, sleep apnea, periodic limb movements or restless legs syndrome * history of neoplastic malignancy within the last 5 years * positive alcohol breath test during the screening visits
efficacy of comb (comprehensive behavioral) model of treatment of trichotillomania

Conditions: Trichotillomania; Hair-Pulling Disorder

Summary: this pilot study is being conducted in order to help make the case for later, more systematic research on the effectiveness of the comprehensive behavioral (comb) model of treating trichotillomania (compulsive hair pulling). the goals are to standardize comb treatment techniques in the form of a clear written manual for therapists; determine whether therapists can use these guidelines in a consistent manner in making treatment decisions; develop and test the reliability of measures of how well therapists are conducting the treatment; and collect preliminary data on the acceptability of the treatment to patients.


Eligibility criteria:
inclusion criteria: * 18 years or older * primary diagnostic and statistical manual, fifth edition (dsm-5) diagnosis of trichotillomania (ttm) exclusion criteria: * current suicidality or severe depression * current psychosis * current alcohol or substance abuse * concurrent psychotherapy for ttm * psychotropic meds (for any disorder) that have not been stable for \>4 weeks

Keywords: trichotillomania hair pulling behavior therapy
an mhealth intervention to improve outcomes for women with hiv/aids

Conditions: HIV/AIDS

Summary: the purpose of this study is: 1. to develop a new mobile health (mhealth) system that will send text messages to remind both pregnant and non-pregnant women with hiv to adhere to their treatment plan (like keeping appointments, fillings prescriptions, and taking their medication) and address individual barriers to hiv care (like stigma, medical mistrust and resilience). 2. the intervention will also include patient navigation and motivational interviewing 2) investigators also want to see if the mhealth system is feasible, easily accepted and if it will impact patient health in a positive way.


Eligibility criteria:
inclusion criteria: * confirmed hiv diagnosis as per the clinic standard * female \>= 18 years old at enrollment * currently active or recently returned into care or newly enrolled * with two or more previously scheduled visits (12 months prior to study enrollment * in the 12 months prior to enrollment: * missed one or more visits or * viral load detectable (\>20 ml) or * not taking prescribed hiv anti-retroviral medications exclusion criteria: * men * women who are cognitively impaired or are not able to consent for themselves * non-working cell phone * adolescents \< 18 years old at enrollment

Keywords: mhealth mobile applications culturally-competent hiv stigma resilience
a study to evaluate efficacy and safety of hcp1803 in patients with essential hypertension

Conditions: Hypertension

Summary: a multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of hcp1803 in patients with essential hypertension


Eligibility criteria:
inclusion criteria: 1. patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions * mean sitsbp \<180 mmhg and mean sitdbp \< 110 mmhg for patients receiving any bp-lowering drug within 1 month prior to visit 1 * 140 mmhg ≤ mean sitsbp \< 180 mmhg and 60 mmhg ≤ mean sitdbp \< 110 mmhg for patients not receiving bp-lowering drugs within 1 month prior to visit 1 2. patients with essential hypertension who meet 140 mmhg ≤ mean sitsbp \< 180 mmhg and 60 mmhg ≤ mean sitdbp \< 110 mmhg at visit 2 exclusion criteria: 1. difference between arms greater than 20 mmhg for mean sitsbp or 10 mmhg for mean sitdbp at visit 1 2. orthostatic hypotension with symptoms within 3 months prior to visit 1. 3. secondary hypertensive patient or suspected to be 4. uncontrolled diabetes mellitus(hba1c \> 9%) or type i diabetes mellitus 5. active gout or hyperuricemia (uric acid ≥ 9mg/dl) 6. severe heart disease or severe neurovascular disease 7. moderate or malignant retinopathy 8. clinically significant hematological finding 9. severe renal diseases (egfr\<30ml/min/1.73m2) 10. severe or active hepatopathy (ast or alt ≥ 3 times of normal range) 11. hypokalemia or hyperkalemia(k\<3.5mmol/l or k ≥ 5.5mmol/l) 12. hyponatremia or hypernatremia(na\<135mmol/l or na ≥ 155mmol/l) 13. hypercalcemia 14. history of malignancy tumor 15. history of autoimmune disease 16. history of alcohol or drug abuse 17. positive to pregnancy test, nursing mother, intention on pregnancy 18. considered by investigator as not appropriate to participate in the clinical study with other reason
two or six cm from pylorus at laparoscopic sleeve gastrectomy

Conditions: Morbid Obesity

Summary: randomized controlled trial comparing between two technique of laparoscopic sleeve gastrectomy for treatment of morbid obesity. in the first technique the investigators started dissection of gastrocolic ligament 6 cm from pylorus and in the second one the distance was only 2 cm. the main primary outcome measure was weight loss.


Eligibility criteria:
inclusion criteria: * morbid obesity with body mass index more than 40 or 35 with at least one comorbidity exclusion criteria: * extreme of age less than 18 or over 65 years contraindications to laparoscopy
treatment of mild class ii malocclusion in adult patients with clear aligners versus fixed multibracket therapy

Conditions: Malocclusion; Class II Malocclusion

Summary: patient with class ii division 1 malocclusion who have mild increased overjet will be treated in this study. the efficacy of clear aligners in the treatment of class ii division 1 malocclusion using intermaxillary elastics will be assessed. the skeletal, dental and soft tissues changes resulted by this intervention will be studied and compared with the results of traditional treatment with fixed appliances. there are two group: 1. a group of patients in which participants will be undergo to the clear aligners with class ii elastics. 2. a group of patients in which participants will be undergo to the traditional fixed appliances with class ii elastics.

patient with class ii division 1 malocclusion who have mild increased overjet will be treated in this study. the efficacy of clear aligners in the treatment of class ii division 1 malocclusion using intermaxillary elastics will be assessed. the skeletal, dental and soft tissues changes resulted by this intervention will be studied and compared with the results of traditional treatment with fixed appliances. there are two group: 1. a group of patients in which participants will be undergo to the clear aligners with class ii elastics. 2. a group of patients in which participants will be undergo to the traditional fixed appliances with class ii elastics. phase intervention/treatment condition or disease not applicable other: clear aligners technique with class ii elastics. other: fixed multibracket appliances with class ii elastics malocclusion class ii division 1 malocclusion

Eligibility criteria:
inclusion criteria: * - patients with permanent occlusion at age 15-20 years. * patients with class ii division i (half cusp or less) with moderate overjet (2-4mm). * patients with normal or horizontal growth pattern. * mild crowding (_\<2 mm) in maxillary and mandibular arch. * patient with satisfactory periodontal health and good oral hygiene * no previous orthodontic treatment * comprehensive medical and dental history ruling out any systemic disease. exclusion criteria: * patients with periodontal disease. * patients with vertical growth pattern. * patients with missing or extracted teeth except third molar. * patients with temporomandibular joint disorder. * patients with skeletal open bite. * patients with poor oral and gingival health * patients with neuromuscular disorder. * patients with severe skeletal class ii.
an exploratory study examining the effects of taking gw679769 once-daily for 4 days in patients with functional dyspepsia

Conditions: Nonulcer Dyspepsia

Summary: this study was designed is to examine the idea that gw679769 has an effect on three of the pathophysiological disturbances reported in patients with functional dyspepsia (fd): impaired stomach accommodation to a meal, delayed stomach emptying, and visceral hypersensitivity to distension.

an exploratory study to investigate the effects of the nk1 antagonist gw679769, 120 mg once daily for 4 days, on gastric accommodation, gastric emptying and gastric distension-induced perception and discomfort in adult male and female patients with functional dyspepsia, in a single-centre, placebo-controlled, double-blind, randomised, two-period crossover study

Eligibility criteria:
inclusion criteria: * functional dyspepsia as diagnosed according to the rome ii criteria * must had a one month trial (full dose) of proton pump inhibitor treatment within the last 6 months, during a symptomatic period, that produced no lasting response, although this may not be required for those patients who have no symptoms of heartburn and do not present pain-predominant dyspepsia symptoms. such decision will be left to the principal investigator's discretion. * patients who are non-smokers or smokers who smoke up to 20 cigarettes per day exclusion criteria: * active or history of peptic ulcer disorder * history of major abdominal surgery * history of underlying psychiatric illness, or current active psychiatric morbidity * pregnant or nursing women

Keywords: functional dyspepsia barostat stomach
early recurrent nasopharyngeal cancer: the effect of surgery vs imrt

Conditions: Recurrent Nasopharyngeal Carcinoma

Summary: this study is a multicenter rct to compare 3-year overall survival(os) rate, progression free survival(pfs),local progression free survival(lpfs),regional progression free survival(rpfs),distant metastasis free survival(dmfs), and toxicities of endonasal endoscopic surgery versus imrt.

local and regional recurrence is a common cause of failure after primary radiotherapy for nasopharyngeal carcinoma. radiotherapy and surgery are the treatments of choice for recurrent npc. this study aims to compare 3 year overall survival(os) rate of surgery versus imrt.a stratified-block randomized approach will be used to randomly assign patients into two treatment groups after stratification according to n staging (n0 vs non-n0). patients with rnpc will be recruited and randomized into two groups in 1:1 ratio. the primary outcomes will be 3 year overall survival(os), the secondary outcome measures will be pfs,lpfs,rpfs,dmfs,and toxicities.assessment will be performed at baseline and during 3 years post-randomization.

Eligibility criteria:
inclusion criteria: 1. diagnosed of recurrent nasopharyngeal carcinoma by pathology or imaging study; 2. stage t1 or t2 according to ajcc 8th edition ; 3. aged 18 to 70 years; 4. without metastasis; 5. previously received 1 course of radiotherapy; 6. without radiotherapy within 1 year, without local treatment for recurrent disease; 7. surgical resectable and imrt suitable; 8. if regional recurrence presented, regional lesion can be treated with local treatments. 9. ecog score 0 or 1; 10. sufficient organ function; 11. acceptable approach of contraception. exclusion criteria: 1. refuse to sign inform consent; 2. radiation encephalopathy or leptomeningeal disease (lmd); 3. history of radioactive particle planting; 4. have uncontrolled intercurrent illnesses which will interfere with the ability to undergo therapy; 5. with prior malignancy (excluding adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer ); 6. any contradiction to surgery; 7. have any co-existing condition that would preclude full compliance or safety with the study; 8. presence of a significant neurological or psychiatric disease, including dementia and seizures; 9. uncontrolled infectious diseases; 10. female patients who are at pregnancy or lactation. 11. without personal freedom or independent civil capacity. 12. with serious autoimmune disease. 13. participants of other interventional clinical trial.

Keywords: endonasal endoscopic surgery radiation therapy nasopharyngeal carcinoma
effect of repeated transcranial magnetic stimulation on aggressive impulsive behavior in patients with borderline personality disorder in a social exclusion paradigm.

Conditions: Borderline Personality Disorder

Summary: patients with a main diagnosis of borderline personality disorder will be recruited and will be randomized for the application of low frequency repeated transcranial magnetic stimulation (rtms) protol or sham rtms protocol. a pre-treatment and post-treatment measurement of the severity of bpd symptoms, impulsivity, and aggressive behavior will be carried out in all participants using self-administered questionnaires. all participants will be asked to participate in a passing ball game (cyberball) with the intention of investigating aspects related to social inclusion / exclusion and measurements will be made regarding planning using the maze test. participation in the cyberball and the assessment of the planning will be carried out before and after the application of the treatment protocol.


Eligibility criteria:
inclusion criteria: * outpatient consultant in the instituto nacional de psiquiatría ramón de la fuente muñiz. * main diagnosis of borderline personality disorder according to dsm-iv-tr. * in the case of having some type of pharmacological treatment using ssris, antipsychotics and / or anticonvulsants, this should be maintained without modifications for at least 2 weeks prior to the start of the study and during the follow-up period. * comorbidity with some other personality disorder according to the scid-ii, with the exception of antisocial personality disorder. * acceptance of participation in the study by signing the informed consent. exclusion criteria: * subjects who did not agree to participate. * diagnosis of current antisocial personality disorder, bipolar disorder, psychotic disorders, severe major depressive episode, substance use disorder (except nicotine), and post-traumatic stress disorder. * presence of any comorbid neurological disorder. * diagnosis of intellectual disability. * subjects in whom the use of rtms is contraindicated: history of seizures, pregnancy, presence of pacemaker, heart disease, and presence of a metallic object. * electroencephalographic evidence of some type of abnormality in the excitability of the central nervous system (dysrhythmias, paroxysmal activity, graphical elements suggestive of epileptic activity, etc.).
single cell leukocyte landscapes and cardiovascular risk in children with chronic kidney disease

Conditions: Chronic Kidney Diseases; Cardiovascular Diseases; Microbial Colonization; Aging

Summary: chronic kidney disease (ckd) is associated with an increased cardiovascular mortality. in particular children with early-onset ckd have a lifelong increased risk to suffer from cardiovascular disease (cvd). therefore, children with ckd deserve our attention. the immune system in children with ckd is disturbed, exhibiting pro-inflammatory features. therefore, we aim to learn more about the characteristics of the immune system in early-onset ckd. in this project pbmc of pediatric ckd patients and age-matched healthy controls will be analysed and compared using cite-seq as a multimodal scrnaseq phenotyping method. all patients will be clinically characterized to integrate cardiovascular and immunological data.


Eligibility criteria:
inclusion criteria: * matching to one of the following groups ckd g3-5: estimated egfr according to schwartz formula \ 90ml/min\*1,73m2 * informed consent to participate in this study exclusion criteria: * body weight of less than 15kg * acute or chronic inflammatory diseases * fever * diabetes * chronic liver disease * inflammatory bowel disease or other gastrointestinal disorders (constipation, diarrhea, short bowel syndrome) * antibiotic prophylaxis or treatment within four weeks prior to recruitment
the effectiveness of adding cupping therapy in patients with nonspecific chronic lumbar pain

Conditions: Low Back Pain, Mechanical; Low Back Pain, Postural; Lower Back Pain Chronic; Low Back Pain, Posterior Compartment

Summary: low back pain is a major public health problem and is associated with a high rate of absenteeism at work, functional disability and frequent use of health services. suction cup therapy is a common technique of traditional chinese medicine (tcm), which has been around for about 3,300 years in asia and the middle east and has as its main feature the decrease in signs and symptoms of chronic pain. the technique was widely used in the 19th century throughout asia and europe, and in recent years demand has been increasing, possibly due to the inefficiency of conventional therapies and medicines. objective: to verify the effectiveness of the suction cup therapy technique associated with conventional physiotherapy in patients with chronic low back pain. method: we will include individuals between 18 and 60 years old, both genders, with low back pain for more than 3 months, without having received physical therapy treatment for a period of 6 months. individuals with severe spinal diseases, root conditions of the spine, carriers of vascular diseases and pregnant women will be excluded. they will be randomly divided into two groups, conventional physiotherapy (group 1) and conventional physiotherapy associated with suction cup therapy (group 2).


Eligibility criteria:
inclusion criteria: * nonspecific chronic low back pain without lower limb irradiation * aged between 18 and 60 years, * both genders * low back pain for more than 3 months * without having received physiotherapy treatment for a period of 6 months exclusion criteria: * individuals with severe spinal diseases (fractures, tumors and inflammatory conditions such as ankylosing spondylitis) * root conditions of the spine (disc herniation and spondylolisthesis with neurological impairment and narrowing of the spinal canal) * root conditions of the spine * carriers of vascular diseases * pregnant women.
a study to evaluate the long-term safety and efficacy of bimekizumab in subjects with psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: this is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis


Eligibility criteria:
inclusion criteria: * in the opinion of the investigator, the subject is expected to benefit from participation in an open label extension (ole) study * subject completed pa0008 without meeting any withdrawal criteria * female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception * male subjects with a partner of childbearing potential must be willing to use a condom when sexually active exclusion criteria: * female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of imp. male subjects who are planning a partner pregnancy during the study or within 20 weeks following the last dose * subjects with any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry * subjects who meet any withdrawal criteria in pa0008. for any subject with an ongoing serious adverse event, or a history of serious infections (including hospitalizations) in the lead-in study, the medical monitor must be consulted prior to the subject's entry into pa0009

Keywords: bimekizumab psoriatic arthritis psa